BioSpace News Archive

Erasca, Inc. announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings.

Oryzon Genomics, S.A. announced a public approval from the EU Commission, under EU State aid rules, of the first Important Project of Common European Interest to support research, innovation and the first industrial deployment of healthcare products, as well as innovative production processes of pharmaceuticals.

Apollomics Inc. announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Gameto has closed an oversubscribed $33 million Series B financing round, led by Two Sigma Ventures with RA Capital and participation from existing investors, including Insight Partners, Future Ventures, and BOLD Capital Partners.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, announced the Prior Approval Supplement submission to the U.S. Food and Drug Administration for ZYNRELEF® extended-release solution Vial Access Needle.

Autobahn Therapeutics today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference in New York on Tuesday, June 4, 2024.

Legend Biotech Corporation today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.

Indica Labs, the global leader in AI-powered digital pathology solutions, announced today the release of the transformative new version of its industry leading life sciences software.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024.

The Foundation for the National Institutes of Health announces two additions to the FNIH Board of Directors: James W. Down, former Vice Chairman of Mercer Management Consulting, and Perry Steiner, Chairman and CEO of Xactus.